C4 Therapeutics, Inc.
CCCC
$4.24
$0.163.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.75% | -15.00% | 112.79% | -26.90% | -46.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.75% | -15.00% | 112.79% | -26.90% | -46.17% |
| Cost of Revenue | -6.59% | -9.11% | -7.16% | -18.37% | 10.29% |
| Gross Profit | 9.65% | 6.96% | 14.89% | 10.42% | -67.99% |
| SG&A Expenses | -1.98% | 0.01% | -11.51% | -24.20% | -9.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.43% | -6.77% | -20.34% | -19.94% | 4.53% |
| Operating Income | 7.29% | 4.73% | 38.62% | 16.16% | -32.92% |
| Income Before Tax | 9.17% | 4.53% | 40.87% | -30.41% | -46.87% |
| Income Tax Expenses | -- | -- | -7.63% | -- | -- |
| Earnings from Continuing Operations | 9.17% | 4.53% | 40.75% | -30.41% | -46.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.17% | 4.53% | 40.75% | -30.41% | -46.87% |
| EBIT | 7.29% | 4.73% | 38.62% | 16.16% | -32.92% |
| EBITDA | 6.29% | 4.62% | 38.98% | 16.48% | -32.83% |
| EPS Basic | 50.66% | 46.37% | 64.18% | -25.12% | -42.29% |
| Normalized Basic EPS | 50.66% | 45.65% | 63.87% | 16.62% | -22.13% |
| EPS Diluted | 50.66% | 46.37% | 64.18% | -25.12% | -42.29% |
| Normalized Diluted EPS | 50.66% | 45.65% | 63.87% | 16.62% | -22.13% |
| Average Basic Shares Outstanding | 84.07% | 77.99% | 65.40% | 4.22% | 3.19% |
| Average Diluted Shares Outstanding | 84.07% | 77.99% | 65.40% | 4.22% | 3.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |